Ubiquitination and ALL: Identifying FBXO8 as a prognostic biomarker and therapeutic target
This work identifies <i>FBXO8</i> as a crucial therapeutic target and prognostic biomarker for ALL. Knockdown of <i>FBXO8</i> led to the suppression of apoptosis and increased tumor growth, suggesting potential therapeutic applications. These results highlight the need for more investigation into ubiquitination-related pathways and offer important new insights into high-risk ALL.
Authors
- Yinting Chen (ORCID: https://orcid.org/0000-0002-0490-5216)
- Zhitao Ye (ORCID: https://orcid.org/0009-0004-7103-8214)
- Danlin Yao (ORCID: https://orcid.org/0000-0002-0963-8700)
- Wei Xian (ORCID: https://orcid.org/0000-0002-3683-7983)
- Yu Zhang (ORCID: https://orcid.org/0009-0005-4213-8045)
- Shuiqing Yu
Institutions
- Zhujiang Hospital (CN)
- Stomatology Hospital (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1554231
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00